Delivery Order SPE2DB22D2206-SPE2DB25FJY04
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,724.87 to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 15 mg/0.5 mL pens on September 9, 2025, with completion scheduled for September 10, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a pharmaceutical supply delivery under DLA's medical procurement operations. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major...
- The Defense Logistics Agency awarded a $3,537.17 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Mounjaro (tirzepatide) 5 mg/0.5 mL pens in 0.5 mL unit doses. The contract, which is a non-set-aside competitive award with an ultimate completion date of July 25, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $1,187.75 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Mounjaro (tirzepatide) 15 mg/0.5 mL pens. This is a firm fixed price, competitively awarded contract with a completion date of August 11, 2025, and represents a child delivery order under AmerisourceBergen's larger prime indefinite delivery contract (IDC) with DLA Troop Support Medical. The work will be performed at the contractor's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Mounjaro (tirzepatide) 10 mg/0.5 mL pens valued at $1,088.36. This is a firm fixed-price delivery order with an ultimate completion date of September 17, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award utilized no set-aside provisions, indicating it was competitively awarded. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $1,170.98 to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 12.5 mg/0.5 mL pen injections on August 29, 2025, with completion scheduled for September 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through the federal procurement process. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order valued at $4,645.08 to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 10 mg/0.5 mL pens on July 22, 2025, with completion scheduled for July 23, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed-price pricing and represents a single delivery order for the diabetes medication to support federal healthcare needs. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $3,109.35 delivery order to AmerisourceBergen Drug Corp on May 27, 2025, for the supply of Mounjaro (tirzepatide) 7.5 mg/0.5 ml pen injections. This is a firm fixed price, non-set-aside contract with an ultimate completion date of May 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $9,733.61 firm fixed-price delivery order to AmerisourceBergen Drug Corp on June 26, 2025, for the supply of Mounjaro (tirzepatide) 5 mg/0.5 ml pens. The contract is non-competitive with no set-aside designation and carries an ultimate completion date of June 27, 2025. AmerisourceBergen will fulfill this delivery order from its corporate office location in Conshohocken, Pennsylvania, serving the federal government's pharmaceutical supply requirements....
- The Defense Logistics Agency awarded a $11,495.12 delivery order to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 5 mg/0.5 mL pens on May 27, 2025, with completion scheduled for May 28, 2025. This competitively awarded, firm fixed-price contract requires delivery to the company's facility in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,482.82 to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 5 mg/0.5 mL pen injectors with an ultimate completion date of August 12, 2025. This non-competitive, firm fixed-price delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken,...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJY04Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,088.36 to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 15 mg/0.5 mL pens on September 15, 2025. This firm fixed-price, non-set-aside delivery order, which is due for completion by September 16, 2025, represents a single transaction under AmerisourceBergen's larger pharmaceutical supply agreement with the federal government. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company serves as a primary pharmaceutical distributor for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive global pharmaceutical support vehicle valued through December 2026. As a prime contractor within the DLA's Medical Supply Chain, AmerisourceBergen supplies an extensive portfolio of pharmaceutical products and medical supplies to support Defense Health Agency operations and other federal healthcare systems worldwide. The company's federal contract history demonstrates consistent capability to fulfill competitive pharmaceutical procurement requirements across multiple therapeutic domains, including specialty diabetes medications such as Mounjaro.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 9/15/25 |